ReviewCureus2025
Optimizing the Use of N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) in the Diagnosis of Heart Failure With Preserved Ejection Fraction (HFpEF): A Clinical Pathway Approach to an Underdiagnosed Entity.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) with preserved ejection fraction (HFpEF) constitutes approximately 50% of all global HF cases and remains one of the most underdiagnosed and undertreated cardiovascular conditions. Diagnosis is often delayed because its symptoms overlap with comorbidities in older adults and the inadequate validation of diagnostic tools for HFpEF. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a recognized biomarker indicative of myocardial wall stress; however, its ideal diagnostic utility in HFpEF is hindered by physiological and comorbid factors, including age, obesity, atrial fibrillation, and renal dysfunction. This review aimed to critically analyze the changing role of NT-proBNP in diagnosing HFpEF, compile recent evidence (2022-2025), and suggest a structured clinical pathway that incorporates adjusted thresholds, clinical scoring systems, and multimodal imaging. By using a step-by-step approach, doctors can improve the diagnostic yield of NT-proBNP, avoid missing or misdiagnosing patients, and speed up the delivery of the right treatment for this complex condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.